EDITOR’S CHOICE

CME: Practical solutions to the antibiotic resistance crisis

Approximately 700 000 people die annually from antibiotic-resistant infections worldwide, and this will rise to 10 million per year by 2050 if our current overuse and misuse of antibiotics is not curtailed. Moreover, if antibiotics are lost, each and every medical procedure that relies on antibiotics to prevent or treat infection will be affected, changing the face of modern medicine as we know it. Far from being a futuristic fantasy, this is already being played out in South African hospitals, leading to closure of wards, cancellation of operating lists, and patients being sent home without operations that they need because of colonisation with multidrug- or pan-drug-resistant bacteria. Welcome to the post-antibiotic era!

This edition of CME focuses on the practical measures that we can take to make antibiotic prescribing appropriate and what needs to be done to prevent infection in the first place, thereby negating their need. These interventions, along with heightened surveillance and reporting of resistance patterns and antibiotic usage, form the battle strategy to defend the efficacy of antibiotics. The antibiotic pipeline, which in terms of new classes of antibiotic has been dry for the past 28 years and for antibiotics against Gram-negative bacteria is not projected to yield a new antibiotic for the next 10 - 15 years, cannot be relied on to save the day. On the contrary, no antibiotic has lasted more than 16 years without resistance developing to it. The emphasis is therefore on preserving what we have through antibiotic stewardship, an intervention that ensures appropriate, optimal antibiotic prescribing, without doing harm to the patient.

SAMJ: Antimicrobial resistance

Ninety years ago, having just discovered penicillin, Alexander Fleming fretted about antimicrobial resistance (AMR). His concerns were well founded – last year, the World Health Organization (WHO) declared that AMR ‘threatens the achievements of modern medicine. A post-antibiotic era – in which common infections and minor injuries can kill – is a very real possibility for the 21st century’. As will be appreciated, some clinical isolates of Mycobacterium tuberculosis, Neisseria gonorrhoeae, Entercoccus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa, and species of Enterobacter, Salmonella and Shigella, are now resistant to most antibiotics.

Antibiotics are used around the world in livestock and fish farming, often in crowded, unclean conditions, to facilitate faster growth and guarantee a cheap food supply. Resistant bacteria can be transferred to humans through contact with livestock, through the food chain, and through waste water from these operations, as well as via wastewater from hospitals and pharmaceutical plants.

By 2050, it is reckoned, over 4 million deaths in Africa will be attributable to AMR (Fig. 1). Since 1987 there has been a relative ‘discovery void’, with only 12 new antibiotics approved since 2000. Because the development of antibiotics, from discovery to human trials, is difficult and expensive, the current stock of antibiotics needs to be conserved and any new ones preserved. Last year the Glaxo CEO stated that pharma was unlikely to spend research funds on discovery of new antibiotics if they were to sit on the shelf for fear of development of AMR upon their use. Fortunately, ‘several small companies, seeking to fill the gap, have had new antibiotics approved, and the world’s fourth-largest drug company recently announced its return to the effort. However, major disincentives remain, including the difficulty of conducting large clinical trials to compare drugs in patients with antibiotic-resistant infections.

In May this year, the World Health Assembly debates the international response to the AMR crisis, namely a Global Action Plan (GAP) for AMR. Adoption of the GAP will follow a year of consultation between a tripartite alliance (comprising the WHO, the Food and Agriculture Organization (FAO) and the World Organization for Animals (OIE)) with governments and all relevant stakeholders.

In this issue of SAMJ we emphasise the crisis of AMR, and seek to warn against administering antibiotics simply because we are unsure of a diagnosis or to satisfy patient demand, especially when the infection may be viral and not bacterial. This is why we are pleased to offer the Working Group of the Infectious Diseases Society of Southern Africa’s updated recommendations for the management of upper respiratory tract infections in South Africa, and devote this month’s CME to antibiotic stewardship.

In this regard, two editorials are key reading, as is the research article by McKay et al. on community- versus healthcare-acquired bloodstream infections at Groote Schuur Hospital, Cape Town, in which local surveillance data are used to support empirical choices of antimicrobials following assessment of whether the infection is community or healthcare acquired. As the Lowman editorial confirms, ‘good ol’ cloxacillin (a far superior drug to vancomycin in the treatment of S. aureus) is still a perfectly suitable option in the right patient. Similarly, with a <5% ESBL rate for Enterobacteraeae associated with community-acquired BSIs, the third- and fourth-generation cephalosporins still have an important role to play.’

Diabetes in children

For children with type 1 diabetes, certain fundamental behaviours are associated with better glycaemic control: frequency of blood glucose (BG) testing (requiring sufficient BG test strips), frequency of insulin injections, absence of insulin omission, adherence to meal planning, and patient-initiated dose adjustments, based on BG testing. Three articles deal with management of diabetes in children and point out the sharp contrast between the status of patients in the public and private sectors. In the public sector children often cope without adult assistance and, lacking a sufficiency of BG test strips, are unable...
to undertake any more than rudimentary BG monitoring; in the private sector they receive education and dietary and exercise advice and have access to the most up-to-date management techniques. Davey and Segal[14] insist that restricted access to BG test strips – so often the case in the public sector – should not be allowed to handicap any patient’s diabetes control efforts.

The simple bread tag – a menace to society
Karro et al.[2] alert us to the dangers of the small rectangle of jagged plastic securing the bag containing a loaf of sliced bread. Three infants in whom a bread tag had lodged in the laryx or subglottis had to be rescued by bronchoscopy. Made of thin plastic, the tags tend to be radiolucent on X-ray and may even be missed on both flexible nasopharyngoscopy and direct laryngoscopy. The authors advise that until redesigned in a safer format, the tags should be removed from the bag of bread and stored out of reach of young children, or donated to Bread Tags for Wheelchairs – The Wheelchair Foundation,[15] which recycles them to buy wheelchairs.

Idiopathic thrombocytopenic purpura (ITP)
First-line treatment of ITP is with oral glucocorticoids, with splenectomy employed as second-line treatment. Newer drugs such as rituximab and thrombopoietin agonists have brought the role of splenectomy into question, particularly as a lethal late complication may be post-splenectomy sepsis. Antel et al.[16] in their article ‘Role of splenectomy for immune thrombocytopenic purpura (ITP) in the era of new second-line therapies’ and in the setting of a high prevalence of HIV-associated ITP confirm that splenectomy should remain the second-line treatment for ITP in most patients, including those with HIV-associated ITP.

Ocular surface squamous neoplasia
Emerging evidence suggests that ocular surface squamous neoplasia (OSSN) that requires surgery may be emerging as an AIDS-defining illness in sub-Saharan Africa. A study of OSSN among HIV-infected patients in Botswana[37] shows that the annual incidence of OSSN increased significantly from 3 cases per 100 000 in 1998 to 7/100 000 in 2004. The authors report on some 500 patients, more than half of whom had AIDS (CD4 counts <200 cells/µL).

This month in the SAMJ...

Marc Mendelson*[1] is Professor of Infectious Diseases at University of Cape Town, President of the Federation of Infectious Diseases Societies of Southern Africa and co-chair of the South African Antibiotic Stewardship Programme. He has worked in partnership with the Department of Health to develop the South African Antimicrobial Resistance Strategic Framework and is now continuing the work towards its implementation.


**Marc Mendelson**[1] is Professor of Infectious Diseases at University of Cape Town, President of the Federation of Infectious Diseases Societies of Southern Africa and co-chair of the South African Antibiotic Stewardship Programme. He has worked in partnership with the Department of Health to develop the South African Antimicrobial Resistance Strategic Framework and is now continuing the work towards its implementation.


